Price movement over the last 24 hours
American Well Corp vs Synopsys, Inc. — how do they compare? American Well Corp trades at $9.7 (market cap $165.58M), while Synopsys, Inc. trades at $452.94 (market cap $85.30B). The key difference: Synopsys, Inc. is far larger — about 515.2× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| AMWL | SNPS | |
|---|---|---|
Market Cap | $165.58M | $85.30B |
Sector | Health | Technology |
52-Week High | $9.91 | $645.59 |
52-Week Low | $3.78 | $380.47 |
Enterprise Value | -$9.66M | $93.66B |
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $9.91, up 8.66% today, with bullish technical signals and positive momentum. The company shows improving financial trends with declining losses and strong gross margins of 52.9%, though it remains unprofitable with a -37.02% net margin. Recent news highlights Amazon's appointment of Amwell's co-founder to lead its healthcare unit, signaling industry validation.
While AMWL shows operational improvement and attractive valuation multiples (P/S 0.68, P/B 0.73), the stock faces headwinds from persistent losses and negative cash flow. Analyst consensus is cautious with a $7.25 price target below current levels, suggesting limited near-term upside despite recent positive momentum.
Synopsys (SNPS) trades at $445.40, up 0.5% on the day, amid a bearish technical signal with support at $432 and resistance at $449. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.35 versus $3.15 expected, and robust revenue growth to $7.05B in 2025. However, net income margin declined to 8.91% from 36.93% in 2024, and cash flow turned negative at -$1.01B due to heavy investing activity.
Outlook remains positive with analyst consensus price target of $558.33 implying 25% upside, supported by the company's strategic pivot to AI-driven design tools. Key risks include execution of the AI transition, high valuation multiples like a P/E of 101.95, and semiconductor cycle volatility. The stock offers growth exposure but requires monitoring of margin trends and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →